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Abstract
Background: Cell-free circulating tumour-derived DNA (ctDNA) can be detected by testing for methylated BCAT1
and IKZF1 DNA, which has proven sensitivity for colorectal cancer (CRC). A prospective correlative biomarker study
between presence of methylated BCAT1 and IKZF1 in tissue and blood was conducted in cases with CRC to explore
how detection of such ctDNA biomarkers relates to cancer characteristics, methylation in tissue and surgical resection
of the primary cancer.
Methods: Enrolled patients with invasive CRC had blood collected at diagnosis, prior to any treatment or surgery
(peri-diagnostic sample). A subgroup of patients also had cancer and adjacent non-neoplastic tissue collected
at surgical resection, as well as a second blood sample collected within 12 months of surgery (post-surgery
sample). DNA was extracted from all samples and assayed for methylated BCAT1 and IKZF1 to determine the
degree of methylation in tissue and the presence of ctDNA in blood.
Results: Of 187 cases providing peri-diagnostic blood samples, tissue was available in 91, and 93 provided at
least one post-surgery blood sample for marker analysis. Significant methylation of either BCAT1 or IKZF1 was
seen in 86/91 (94.5%) cancer tissues, with levels independent of stage and higher than that observed in adjacent
non-neoplastic specimens (P < 0.001). ctDNA methylated in BCAT1 or IKZF1 was detected in 116 (62.0%) cases at
diagnosis and was significantly more likely to be detected with later stage (P < 0.001) and distal tumour location
(P = 0.004). Of the 91 patients who provided pre-and post-surgery blood samples, 47 patients were ctDNA-positive at
diagnosis and 35 (74.5%) became negative after tumour resection.
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Conclusion: This study has shown that BCAT1 and IKZF1 methylation are common events in CRC with almost all cancer
tissues showing significant levels of methylation in the two genes. The presence of ctDNA in blood is stage-related and
show rapid reversion to negative following surgical resection. Monitoring methylated BCAT1 and IKZF1 levels could
therefore inform adequacy of surgical resection.
Trial registration: Australian New Zealand Clinical Trial Registry number 12611000318987. Registered 25 March 2011.
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Background
Colorectal cancer (CRC) is the second leading cause of
death from cancer in the developed world [1]. Even
though most CRC patients achieve remission with initial
treatment, more than 25% will suffer recurrence [2].
Therefore, to achieve early detection of recurrence, pa-
tients are usually entered into a follow-up regimen includ-
ing regular blood testing, radiology and colonoscopy. The
current blood biomarker used, carcinoembryonic antigen
(CEA), has limited sensitivity and specificity for recur-
rence [3, 4]. Better blood markers for adequacy of initial
therapy should aid identification of subjects at risk of re-
currence or in need of extended initial therapy such as
addition of or prolongation of chemotherapy. These
markers should be present in all colorectal tumours re-
gardless of the genetic alterations and should be absent
from the blood following complete surgical resection of
the tumour.
Somatic and epigenetic alterations of DNA are associ-
ated with CRC development, and a number of studies
show that tumour-derived DNA can be detected in the
cell-free fraction of blood (circulating tumour DNA,
ctDNA) [5–8]. Detecting ctDNA by assaying for somatic
mutations [9, 10] has the potential to inform response to
therapy, existence of minimal residual disease and devel-
opment of metastases [11, 12]. However, none of the
common somatic mutations linked to CRC development
occurs universally, and all appear with a low frequency
[5, 13]. Furthermore, the mutation profile becomes more
heterogeneous as the cancer evolves over time, whereas
epigenetic markers are more stable during oncogenesis
[5]. Thus, aberrant DNA methylation, which occurs fre-
quently in CRC [5, 6] might more reliably inform re-
sponse to therapy and presence of residual disease.
A panel of methylated DNA biomarkers shown to have
good sensitivity and specificity for CRC is BCAT1
(branched chain amino acid transaminase 1) and IKZF1
(IKAROS family zinc finger 1) [14–16]. Deregulation of
IKZF1 and BCAT1 is involved in tumour growth and in-
vasiveness in several cancers, including CRC [6, 17].
There is a biological plausibility that methylated BCAT1
and IKZF1 may be more significant in oncogenesis than
simply epiphenomena resulting from disturbances in
gene methylation processes as both play an important
functional role in maintaining a healthy state in normal
tissue [18–20]. BCAT1 controls the metabolism of
branched chain amino acids which are essential nutri-
ents for growth, and it has been demonstrated that when
BCAT1 expression is blocked, the lifespan increases
nearly 25% in nematodes [21]. The BCAT1 gene locus is
aberrantly methylated in several pathologies, including
CRC [20, 22] where abnormal expression has been re-
ported to be a predictor of distant metastases [17].
IKZF1 encodes a DNA-binding protein, which during
normal development restricts the G1-S transitioning of
the cell cycle by regulating a small set of cell cycle regu-
lator genes [23, 24]. IKZF1 mutations and deletions lead-
ing to generation of isoforms lacking DNA binding
capability are common in hematologic neoplasia, e.g.
lymphoblastic leukemia where such mutations/deletions
abolish cell cycle control and leads to hyperproliferation.
In CRC, IKZF1 promoter methylation has been linked to
loss of proper regulation of proliferation and differenti-
ation [24].
If detection of methylated BCAT1/IKZF1 ctDNA is to
be useful in patient management, it is important to bet-
ter understand the principles underlying the presence of
these epigenetic markers in blood and how this relates
to tissue expression and to tumour debulking. The aim
of this study was therefore to assess the relationship
between tissue levels and detection in blood and to




This was a prospective observational study of cases with
invasive CRC that examined the relationship of ctDNA
status with clinicopathological measures and with levels
of methylated BCAT1 and IKZF1 DNA in surgically
resected tissues. In addition, the effect of surgical resec-
tion on ctDNA status was assessed. A methylation-
specific validated real-time PCR-based method was used
to assess the presence of methylated BCAT1 and IKZF1
in bisulphite-converted DNA isolated from plasma [25].
The degree of methylation of BCAT1 and IKZF1 DNA
were also measured in tissue (tumour and adjacent non-
neoplastic epithelium).
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The study was approved by the Southern Adelaide
Clinical Human Research Ethics Committee (reference
number 134.045). Written informed consent was ob-
tained from all participants. The study is registered at
Australian and New Zealand Clinical Trials Registry
(#12611000318987).
Population
Any adults (18 years of age or older) who were recently
diagnosed with invasive colorectal adenocarcinoma
(AJCC stages I–IV) at Flinders Medical Centre (Bedford
Park, SA, Australia) or Repatriation General Hospital
(Daw Park, SA) were approached about volunteering for
the study during 2011–2016. Following consent, patients
were enrolled in the study provided that they met diag-
nostic criteria for invasive colorectal adenocarcinoma,
were adequately staged, and were provided a blood sam-
ple prior to any treatment (the peri-diagnostic sample).
Diagnosis and extent of disease were determined on the
basis of colonoscopy and other clinicopathological find-
ings. CRC were staged (following AJCC and TNM) [26],
and distal tumours were classed as those distal to the
transverse colon.
Clinical procedures
Venous blood for ctDNA testing was collected into
two 9 mL K3EDTA Vacuette tubes (Greiner Bio-One,
Frickenhausen, Germany) prior to any treatment in-
cluding primary surgery from 187 participants (“peri-
diagnostic plasma sample”) and when feasible at
subsequent clinical review within 12 months after sur-
gery from 93 participants (“post-surgery plasma sam-
ple”). Blood collection tubes were kept on ice prior to
plasma processing (no more than 4 h from blood col-
lection). Plasma was prepared by centrifugation at
1500g for 10 min at 4 °C (deceleration at lowest setting),
followed by retrieval of the plasma fraction and a repeat
centrifugation. The resulting plasma was stored at − 80 °C.
Frozen plasma samples were shipped on dry ice to Clinical
Genomics (North Ryde, NSW, Australia) and stored at −
80 °C until testing.
Resected tissue samples were also available for a sub-
group of patients who had received no neoadjuvant ther-
apy (n = 91). Samples collected were fresh (non-fixed)
non-necrotic cancer tissue and adjacent non-neoplastic
tissue (greater than 10 mm from the tumour, median
75 mm) which were obtained by a supervising patholo-
gist. Samples were stored in RNAlater (Thermo Fisher
Scientific Australia) for at least 48 h at 4 °C before
stored at − 80 °C until further analysis.
No study-wide control of radiological imaging, path-
ology procedures, or quality was undertaken as the study
aimed to assess marker performance relative to outcomes
determined in usual clinical practice. All procedures were
performed by hospital-accredited specialists and so met
site-specific standards for venipuncture, monitoring, im-
aging and equipment.
Methylation testing
For ctDNA testing, cell-free circulating DNA was ex-
tracted from 4.5 mL plasma using the QIASymphony
Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany)
and bisulphite-converted using the EpiTect Fast Bisulphite
Conversion kit (Qiagen) as previously described [16]. The
resulting bisulphite-converted DNA was simultaneously
analyzed in triplicate using a real-time multiplex PCR
assay simultaneously detecting a methylated region in
BCAT1 and IKZF1 as well as a region in ACTB (proxy
measure of the total amount of DNA) using a Light-
Cycler 480 II instrument (Roche Diagnostics, IN,
USA) [16, 25, 27]. We have previously shown this assay
to be sensitive for the detection of low copy numbers of
the methylated genes [25]. A blood sample was deemed
ctDNA positive for clinical purposes if at least one PCR
replicate was positive for methylated BCAT1 and/or
IKZF1 [16, 27].
For tissue DNA analysis, DNA was extracted from 10
to 20 mg tissue according to the manufacturer’s instruc-
tions (DNAeasy® Blood & Tissue kit, Qiagen), except for
using 40 μL Proteinase K and a lysis time of 3 h at 56 °C.
DNA (500 ng) was bisulphite-converted using an EpiTect
Fast 96 Bisulphite Conversion kit (Qiagen) as previously
described [16] with the exception of omitting carrier RNA
and a 30 μL elution.
When consideration was given to percentage of meth-
ylated ctDNA, the level was expressed as the ratio of
total mass of BCAT1 and IKZF1 measured in total
amount of DNA volume. A sample was deemed positive
when the %methylation was above the 75th percentile
value of BCAT1 and IKZF1 of the non-neoplastic tissue
(9.7% for BCAT1 and 0.5% for IKZF1).
Statistical analyses
Hypothesis testing included Mann-Whitney, Kruskal-
Wallis, chi-square and Fisher’s exact tests. Analyses were
performed using two-sided tests, and a significance level
of less than 5% was considered statistically significant.
The binomial distribution was assumed for calculations
of exact 95% confidence intervals (95%CI). All analyses
were performed using Stata, version 13.1.
Once the data was collected, a power analysis was per-
formed for a logistic regression analysis to compare the
blood positivity across different cancer characteristics.
The analysis was performed using a z test with a bino-
mial distribution, an alpha of 5%, plasma positivity of
62% and a proportion comparison of 0.5 to 0.7. A power
of 0.78 was estimated.
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Logistic regression was used for multivariate analysis.
Variables that were included were those where the rela-
tionship with the outcome was significant at P ≤ 0.1 in
the univariate analysis or had been shown in previous
studies to be clinically significant. Age, tumour size,
lymphatic invasion, perineural invasion, extramural vas-
cular invasion, intramural vascular invasion and differen-
tiation were included in the multivariate analysis. The
final model was prepared using a backward selection




Figure 1 shows the disposition of 442 patients approached.
The characteristics of cases according to clinical informa-
tion and specimen availability are summarized in
Additional file 1: Table S1. The stage distribution
differed between all cases and just those cases pro-
viding a post-surgical blood sample as not all stage
IV cases proceeded to surgery.
Peri-diagnostic ctDNA status
Peri-diagnostic blood samples were available for 187
cases, and 116 (62.0%, 95%CI 54.7–69.0) tested positive
for methylated BCAT1 and/or IKZF1. When methylation
changes were assessed for different clinicopathological
features, similar results were seen for BCAT1 and IKZF1
except for location where BCAT1 had a higher positivity
rate with distally located tumours (Table 1). Overall
ctDNA positivity varied by AJCC and TNM staging, size,
location and lymphatic invasion by univariate analysis
(Table 1). CRC stages II, III and IV were strong predic-
tors for ctDNA positivity compared to stage I. After
multivariate modeling, only stage and location remained
as significant predictors; patients with tumours located
in the distal colon or rectum were 3.0 times more likely
to be ctDNA positive than those with proximal tumours
(95% CI 1.4–6.2) (Table 2).
Methylation in colonic tissue
Tumour tissue was available in 91 cases, with matched
non-neoplastic tissue in 87. Cancer tissues exhibited sig-
nificantly greater methylation than adjacent non-
neoplastic tissues (P < 0.001 for each marker; Fig. 2). De-
tectable methylation in one or both genes was present in
98.9% (90/91) of cancer tissue, with methylated BCAT1
present in 89/91 (97.8%) and methylated IKZF1 present
in 79/91 (86.8%). The one tumour that was negative for
both BCAT1 and IKZF1 methylation had a single som-
atic mutation in MSH2 and MSH6. Using the upper IQR
values measured in non-neoplastic tissues as positivity
thresholds, hypermethylation of BCAT1 and IKZF1 was
observed in 82/91 (90.1%) and 75/91 (82.4%) of cancers,
respectively, with 86/91 (94.5%) having elevated levels
for either marker. The only variables having any effect
on methylation levels in cancers were age older than
65 years and tumour location for BCAT1 (Table 3).
These differences were not seen in non-neoplastic tissue
(P > 0.05, data not shown).
Comparison of tumour tissue methylation and peri-diagnostic
ctDNA status
For the subgroup of patients who had surgical tissue
assayed, there was no difference in methylation in
tumour tissue between the 56 ctDNA-positive and 35
ctDNA-negative cases at peri-diagnosis (median (IQR):
BCAT1, 43.4% (27.1–59.2) and 52.6% (26.1–68.2), respect-
ively, P = 0.533; IKZF1, 59.3% (20.5–84.4) and 59.0%
(16.6–100.3), respectively, P = 0.430). Detection of
ctDNA was not concordant with tissue levels; levels
of tissue methylation were not dependent on stage,
whereas detection in blood was (Fig. 3). Most tumour
tissues displayed elevated methylation of both BCAT1
and IKZF1 (n = 78, 85.7%), while ctDNA methylated
in both genes was only detected in 30 patients (33.0%)
(Additional file 1: Table S2).
Post-surgery ctDNA status
Plasma was available in 93 cases for detection of methyl-
ated ctDNA within 12 months of surgery (median (IQR)
1.9 months (1.6–4.0 months), Additional file 1: Figure S1).
Thirty-five (74.5%) of the 47 cases who were ctDNA posi-
tive prior to surgery became negative after resection as
shown in Fig. 4; plasma was collected in 26 of these within
3 months of surgery, indicating that reversion to a nega-
tive ctDNA status occurred rapidly. In the 12 cases who
failed to revert to negative, eight had not received their full
cancer treatment (i.e. adjuvant chemotherapy or resection
of distant metastases) at the time of the blood collection.
Discussion
This study explored how the methylated BCAT1 and
IKZF1 DNA biomarkers for ctDNA related to cancer
characteristics, aberrant methylation in CRC tissue and
surgical resection as understanding these relationships
might aid management of patients diagnosed with CRC
by informing completeness of surgical resection.
For a ctDNA marker to be useful, the measured mo-
lecular features (e.g. mutation or methylation) should be
present in the majority of cancer tissues and ideally
should be independent of location, stage and molecular
pathogenesis. Percentage methylation of either marker
was much higher in cancer than non-neoplastic tissue,
indicating that this was not a field effect. Our observa-
tions showed that all but one tumour had detectable
methylation, with tumour tissue levels being independ-
ent of stage. The variables that related to degree of
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methylation in tissue was cancer compared to non-
cancer tissue (either marker), age (lower methylation in
younger people in cancer tissue, BCAT1 only) and
tumour location (higher methylation in proximal loca-
tions, BCAT1 only). IKZF1 also had slightly higher
methylation levels in proximal cancers, but this did not
reach statistical significance. Genome-wide hypermethyla-
tion has previously been reported to be more pronounced
in proximal tumours than distal tumours [28]. Despite
these differences in quantitative levels, there were no dif-
ferences in the proportion of cancers considered positive
for each methylated biomarker (i.e. with %methylation
above the 75th percentile of non-neoplastic tissue). In
addition, these differences were not reflected in the blood
results, with distal tumours more likely to be ctDNA
positive, which is likely to be related to morphological
differences. Thus, BCAT1 or IKZF1 hypermethylation
of tissue is common at all stages of CRC and appears
to be more frequent than the somatic mutation fre-
quency reported for known hot-spot genes such as
KRAS, TP53 and APC [5, 13].
ctDNA blood tests (regardless of whether the marker
is genetic or epigenetic) appear to be limited in their
capacity to detect stage I cases compared to all other
stages [12, 29, 30]. There was only one patient who was
negative for both methylated BCAT1 and IKZF1 in the
Fig. 1 Disposition of study cohort. Peri-diagnostic blood collection refers to sampling either prior to diagnostic procedure or between that and surgery
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tissue and who also returned a negative blood result. We
report sensitivity for CRC of 62% across all stages, and
the test was significantly more likely to be positive with
more advanced clinical stage of cancer, which is consistent
with our earlier findings [15, 16] and other commonly
used CRC screening tests. In brief, we previously reported
that at a matching specificity, the BCAT1/IKZF1 blood
test had equal sensitivity to a commonly used faecal
Table 1 Plasma BCAT1, IKZK1 and overall ctDNA positivity for different clinicopathological findings of patients with invasive colorectal
cancer (n = 187)














Age < 65 years 67 29 43.3 (31.2–56.0) 0.154 28 41.8 (29.8–54.5) 0.332 39 58.2 (45.5–70.2) 0.421
≥ 65 years 120 65 54.2 (44.8–63.3) 59 49.2 (39.9–58.4) 77 64.2 (54.9–72.7)
Gender Female 75 34 45.3 (33.8–57.3) 0.270 31 41.3 (30.1–53.3) 0.244 42 56.0 (44.1–67.5) 0.164
Male 112 60 53.6 (43.9–63.0) 56 50.0 (40.4–59.6) 74 66.1 (56.5–74.7)
Stage I 40 4 10.0 (2.8–23.7) < 0.001 2 5.0 (0.6–16.9) < 0.001 6 15.0 (5.7–29.8) < 0.001
II 54 29 53.7 (39.6–67.4) 25 46.3 (32.6–60.4) 35 64.8 (50.6–77.3)
III 63 37 58.7 (45.6–71.0) 36 57.1 (44.0–69.5) 47 74.6 (62.1–84.7)
IV 30 24 80.0 (61.4–92.3) 24 80.0 (61.4–92.3) 28 93.3 (77.9–99.2)
T stage T1 26 2 7.7 (0.9–22.1) < 0.001 1 3.8 (0.1–19.6) < 0.001 2 7.7 (0.9–25.1) < 0.001
T2 23 6 26.1 (10.2–48.4) 3 13.0 (2.8–33.6) 8 34.8 (16.4–57.3)
T3 96 55 57.3 (46.8–67.3) 56 58.3 (47.8–68.3) 69 71.9 (61.8–80.6)
T4 34 24 70.6 (52.5–84.9) 21 61.8 (43.6–77.8) 29 85.3 (68.9–95.0)
Unknown 8 7 87.5 (47.3–99.7) 6 75.0 (34.9–96.8) 8 100.0 (63.1–100.0)
N stage N0 100 41 41.0 (31.3–51.3) 0.024 36 36.0 (26.6–46.2) 0.007 50 50.0 (39.8–60.2) 0.001
N1/N2 73 44 60.3 (48.1–71.5) 44 60.3 (48.1–71.5) 56 76.7 (65.4–85.8)
Unknown 14 9 64.3 (35.1–87.2) 7 50.0 (23.0–77.0) 10 71.4 (41.9–91.6)
M stage M0 147 66 44.9 (36.7–53.3) 0.002 58 39.5 (31.5–47.8) < 0.001 82 55.8 (47.4–64.0) 0.001
M1 30 24 80.0 (61.4–92.3) 24 80.0 (61.4–92.3) 28 93.3 (77.9–99.2)
Unknown 10 4 40.0 (12.2–73.8) 5 50.0 (18.7–81.3) 6 60.0 (26.2–87.8)
Size (mm) < 20 mm 14 2 14.3 (1.8–42.8) < 0.001 2 14.3 (1.8–42.8) < 0.001 3 21.4 (4.7–50.8) < 0.001
20–50 mm 100 44 44.0 (34.1–54.3) 37 37.0 (27.6–47.2) 56 56.0 (45.7–65.9)
> 50 mm 65 44 67.7 (54.9–78.8) 45 69.2 (56.6–80.1) 52 80.0 (68.2–88.9)
Unknown 8 4 50.0 (15.7–84.3) 3 37.5 (8.5–75.5) 5 62.5 (24.5–91.5)
Location Proximal 75 28 37.3 (26.4–49.3) 0.011 31 41.3 (30.1–53.3) 0.306 37 49.3 (37.6–61.1) 0.011
Distal 111 65 58.6 (48.8–67.8) 56 50.5 (40.8–60.1) 78 70.3 (60.9–78.6)
Unknown 1 1 100.0 (2.5–100.0) 0 0.0 (0.0–97.5) 1
Lymphatic invasion Yes 38 24 63.2 (46.0–78.2) 0.014 25 65.8 (48.6–80.4) 0.001 30 78.9 (62.7–90.4) 0.002
No 121 49 40.5 (31.7–49.8) 44 36.4 (27.8–45.6) 61 50.4 (41.2–59.6)
Perinueural invasion Yes 20 9 45.0 (23.1–68.5) 0.860 10 50.0 (27.2–72.8) 0.541 15 75.0 (50.9–91.3) 0.104
No 138 65 47.1 (38.6–55.8) 59 42.8 (34.4–51.4) 77 55.8 (47.1–64.2)
Extramural vascular
invasion
Yes 9 6 66.7 (29.9–92.5) 0.313 7 77.8 (40.0–97.2) 0.054 8 88.9 (51.8–99.7) 0.089
No 178 88 49.4 (41.9–57.0) 80 44.9 (37.5–52.6) 108 60.7 (53.1–67.9)
Intramural vascular
invasion
Yes 3 2 66.7 (9.4–99.2) 0.567 2 66.7 (9.4–99.2) 0.481 2 66.7 (9.4–99.2) 0.868
No 184 92 50.0 (42.6–57.4) 85 46.2 (38.8–53.7) 114 62.0 (54.5–69.0)
Differentiation Poor 34 21 61.8 (43.6–77.8) 0.241 20 58.8 (40.7–75.4) 0.124 25 73.5 (55.6–87.1) 0.160
Moderate 118 54 45.8 (36.6–55.2) 48 40.7 (31.7–50.1) 67 56.8 (47.3–65.9)
Well 14 6 42.9 (17.7–71.1) 6 42.9 (17.7–71.1) 7 50.0 (23.0–77.0)
Unknown 21 13 61.9 (38.4–81.9) 13 61.9 (38.4–81.9) 17 81.0 (58.1–94.6)
1Confidence interval
2P value, Pearson’s chi-square test
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immunochemical test (62 versus 64%, respectively) [16].
There are two commercially available molecular tests for
CRC screening, ColoGuard (multi-target stool DNA test,
including two methylation markers) and ProColon (meth-
ylated SEPT9). The multi-target stool DNA test has a re-
ported sensitivity of 92% [31] but a lower specificity (87%)
than what we report for the BCAT1/IKZF1 blood test
(92%) [16]. The estimated sensitivity and specificity for the
ProColon blood test is 48 and 92%, respectively [30].
Our results show clearly that absence of BCAT1 or
IKZF1 in blood at diagnosis does not reflect an absence
of marker methylation in the tissue. Consequently, infre-
quent aberrant methylation is not likely to be a limiting
factor for the BCAT1/IKZF1 blood test. It is not clear if
the usefulness of ctDNA testing for primary diagnosis is
somehow biologically limited in early cancer and
dependent on tissue vascularity, invasion or cellular
turnover (e.g. apoptosis or necrosis). It is also uncertain
if ctDNA biomarker assays are technologically limited in
assay sensitivity, or if they will vary in usefulness be-
tween specific markers. However, it is likely that com-
plex panels will be needed for ctDNA tests assaying for
the less frequent somatic mutations, whereas ctDNA
tests assaying for just a few methylation markers, such
as those reported here, are sufficient. The literature is
sparse on direct paired comparison studies (tissue versus
blood), especially for methylation biomarkers. Using
other molecular markers of cancer (microRNA, mRNA),
Wang et al. reported the circulating levels of miR-601
and miR-760 to be significantly lower in CRC patients
compared to that of healthy subjects, yet they found no
differences in the expression levels of these miRNA
markers between cancer and non-cancer tissues [32].
Conversely, good concordances have been reported for
colorectal neoplastic tissue and plasma detection for
CRC biomarkers such as TYMS and LISCH7 mRNAs,
[33, 34] KRAS mutation and SEPT9 methylation, [35]
albeit the levels in plasma were much lower than that
found in tissue. For Sept9, methylation rates were 64.5% in
tissue and 14.5% in plasma, while KRAS mutation
was found in 33.6% of tissues and 2.9% of plasma
samples [35].
There is considerable interest in understanding the as-
sociation between ctDNA and detection of minimal re-
sidual disease and likelihood of overall recurrence and
survival [9, 36]. In this respect, the epigenetic markers
we applied showed that three quarters of patients who
were ctDNA positive at diagnosis became negative after
Table 2 Association between tumour characteristics and ctDNA
positivity







Proximal colon 1 (reference)
Distal colon and rectum 3.0 (1.4–6.2)
Fig. 2 BCAT1 and IKZF1 methylation in cancer and adjacent non-neoplastic tissues. Matching data points are indicated by connecting lines.
“%methylation”—level of methylated BCAT1 (a) or IKZF1 (b) in 5 ng bisulphite-converted tissue DNA. “Adj. non-CRC”—adjacent non-neoplastic tissue.
Cross hairs—median %methylation (horizontal line) and interquartile range (IQR, vertical line), with upper IQR for non-neoplastic tissue represented by
the horizontal dotted line
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surgical resection. Many of the patients who remained
positive had not completed their cancer treatment. The
effect of surgical resection on detectable biomarker in
blood adds credibility to the premise that these markers
could be useful for monitoring of patients in that they
are responsive to debulking. This observational study
has been conducted in a usual-care moderate-sized clin-
ical service where follow-up protocols are subject to
variance according to practitioner protocols and risk for
recurrence, rather than in the context of a formal highly
structured prospective clinical trial where blood would
be collected at set intervals following surgery and other
Table 3 BCAT1 and IKZF1 methylation in 91 cancer tissue samples according to case demographics and tumour characteristics
%Methylation, median (IQR)
Variable factor Category N BCAT1 P IKZF1 P
Age < 65 32 35.8 (14–57.5) 0.0391 52.5 (11.4–69.7) 0.1431
≥ 65 59 50.1 (31.4–67.8) 64.8 (31.3–96.3)
Gender Female 45 46.9 (31.0–60.7) 0.4441 59 (41.6–96.3) 0.3591
Male 46 42.2 (26.9–63.1) 59.3 (10.7–83.3)
Stage I 19 50.1 (19.8–81.3) 0.5812 56.9 (9.1–115.6) 0.6592
II 34 44.6 (20.2–58.9) 48.7 (0.5–82)
III 29 43.3 (32.9–51.9) 61.1 (42.6–84.7)
IV 9 57.7 (36.1–71.4) 54.3 (41.4–98.7)
T stage T1 8 68.6 (54.4–93.0) 0.0662 88.7 (34.4–132.4) 0.3622
T2 13 27.5 (18.8–51.4) 32.1 (9.1–100.3)
T3 48 50.5 (32.7–60.0) 65.1 (31.8–84.0)
T4 22 32.6 (23.6–52.9) 42.1 (10.7–69.0)
N stage N0 57 50.9 (26.9–63.3) 0.6802 63.4 (15.8–97.8) 0.5382
N1/N2 33 43.3 (30.3–59.4) 59 (41.4–76.1)
Nx 1 26.9 (26.9–26.9) 9.1 (9.1–9.1)
M stage M0 79 44.8 (26.9–63.1) 0.2822 60.8 (18.5–91) 0.7852
M1 9 57.7 (36.1–71.4) 54.3 (41.4–98.7)
Mx 3 31.7 (18.8–35.4) 50.3 (0.0–85.5)
Size (mm) < 20 mm 4 59.6 (34.9–103.7) 0.5512 68.5 (14.3–152.9) 0.8562
20–50 mm 52 41.5 (27.9–57) 57 (16.2–88.3)
> 50 mm 34 47.8 (23.6–67.8) 62.1 (28–84.7)
Unknown 1 81.3 (81.3–81.3) 68.8 (68.8–68.8)
Location Proximal 50 51.6 (31.0–67.3) 0.0291 68.9 (41.6–98.7) 0.0551
Distal 41 37.9 (19.8–51.9) 41.4 (16.6–68.8)
Lymphatic invasion Yes 25 42.2 (33.9–63.1) 0.6501 63.4 (40.8–85.5) 0.8271
No 66 48.3 (26.9–58.9) 57 (18.5–91)
Perineural invasion Yes 13 37.9 (19.9–56.4) 0.6261 41.4 (10.7–84.7) 0.7081
No 78 48.3 (27.4–63.1) 59.9 (28.5–96.1)
Extramural vascular invasion Yes 4 42.0 (32.2–67.2) 0.8161 56.8 (24.6–102.3) 0.8161
No 87 44.8 (26.9–63.1) 59.0 (18.5–91.0)
Intramural vascular invasion Yes 1 28.3 (28.3–28.3) 0.4461 41.2 (41.2–41.2) 0.5941
No 90 45.8 (26.9–63.1) 59.9 (18.5–91.0)
Differentiation Poor 26 47.4 (30.3–67.8) 0.3202 59.9 (32.6–96.3) 0.6912
Moderate 53 44.8 (26.9–58.9) 57.1 (12.0–83.3)
Well 7 36.1 (19.8–39) 48.7 (18.5–70.6)
Unknown 5 56.2 (51.4–63.3) 81.2 (76.3–84.7)
1Mann-Whitney test on medians (two-tailed)
2Kruskal-Wallis test on medians (two-tailed)
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therapies. Future prospective studies with tightly con-
trolled and more frequent venipuncture would clarify
the best time to draw blood after surgery, but it seems
possible that it could be within 3 months, as most of the
cases became negative within this time frame. A small
study investigating the effect of surgery on mutation
markers of ctDNA reported that cases became negative
within 3 to 5 days [37]. All these observations are con-
sistent with the estimated short half-life of circulating
DNA [38] and indicate that these markers are highly and
quite rapidly responsive to surgical debulking and thus
adds credibility to the premise that these methylation
markers are applicable for dynamic monitoring of re-
sidual disease [29]. As this study focused on the effects
of surgery on ctDNA clearance, the length of follow-up
was consequently not long enough to show what our
findings mean for clinical outcomes such as risk for
recurrence and death.
Conclusions
Non-invasive analysis of ctDNA for post-treatment
surveillance has the potential to become a practice-
changing tool as it may create a window of opportunity
for intervention at time points where curative modalities
Fig. 3 The case-by-case relationship between methylation in tissue and ctDNA positivity according to cancer stage. The top grey panel shows ctDNA
positivity; open diamonds, ctDNA negative; black/white, BCAT1 positive only; white/red, IKZF1 positive only; and black/red, ctDNA methylated in both
genes. The bottom panel shows graphical representation of methylation levels in cancer tissues (closed circles: black, BCAT1; red, IKZF1). Tissues with no
detectable BCAT1 and/or IKZF1 are indicated with open circles
Fig. 4 ctDNA status before and after resection of the primary cancer. The levels of ctDNA after surgery (within 12 months) are reported for the 47
cases who were positive for BCAT1 and/or IKZF1 ctDNA prior to surgical resection. Black circles, ctDNA positive cases before resection (n = 47); red
circles, cases who tested ctDNA positive after resection (n = 12); grey circles, cases who tested ctDNA negative after resection (n = 35)
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are still an option. Our findings demonstrate that detec-
tion of ctDNA using this noninvasive test for methylated
BCAT1/IKZF1 is informative with respect to complete-
ness of surgical resection. Hypermethylation in the two
investigated genes are near ubiquitous in CRC tissue,
and their appearance in the blood as markers of ctDNA
is related to cancer behavior (stage) and is not limited by
lack of tissue expression. Testing for ctDNA by measur-
ing for appearance of methylated BCAT1/IKZF1 could
aid patient management through selection of cases for
intensified surveillance for recurrence and might allow
identification of patients who would benefit from adjust-
ments in adjuvant therapies.
Additional files
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Table S2. Concordance between detection of methylated BCAT1 and IKZF1 in
tissues and blood. Figure S1. ctDNA status before and after surgical resection
for 93 cases. (DOCX 36 kb)
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